Since thrombospondin-1 stimulates cell migration and may potentially contribute to the spread of cancer, blocking TSP1–CD47 interaction may be another novel therapeutic approach in CTCL. This evidence concerns the gene CD47 and primary cutaneous T-cell non-Hodgkin lymphoma.